-
1
-
-
41149166182
-
Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring
-
18337732 10.1038/nrc2351
-
Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268-78.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 268-278
-
-
Lilja, H.1
Ulmert, D.2
Vickers, A.J.3
-
2
-
-
78649362120
-
EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease
-
21056534 10.1016/j.eururo.2010.10.039
-
Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61-71.
-
(2011)
Eur Urol
, vol.59
, pp. 61-71
-
-
Heidenreich, A.1
Bellmunt, J.2
Bolla, M.3
-
3
-
-
23944492852
-
Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis
-
15982797 10.1016/j.eururo.2005.04.015
-
Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386-99.
-
(2005)
Eur Urol
, vol.48
, pp. 386-399
-
-
Roddam, A.W.1
Duffy, M.J.2
Hamdy, F.C.3
-
4
-
-
33646009994
-
A meta-analysis of the performance characteristics of the free prostate-specific antigen test
-
Free PSA Study Group et al. 16600352 10.1016/j.urology.2005.10.052
-
Lee R, Localio AR, Armstrong K, Free PSA Study Group, et al. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 2006;67:762-8.
-
(2006)
Urology
, vol.67
, pp. 762-768
-
-
Lee, R.1
Localio, A.R.2
Armstrong, K.3
-
5
-
-
0030339750
-
Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values
-
8950358 10.1002/(SICI)1097-0045(1996)7+<3: AID-PROS1>3.0.CO;2-T
-
Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl. 1996;7:3-16.
-
(1996)
Prostate Suppl
, vol.7
, pp. 3-16
-
-
Semjonow, A.1
Brandt, B.2
Oberpenning, F.3
Roth, S.4
Hertle, L.5
-
6
-
-
0029240414
-
Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994
-
7531897 10.1016/0090-4295(95)80001-8
-
Stamey TA. Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology. 1995;45:173-84.
-
(1995)
Urology
, vol.45
, pp. 173-184
-
-
Stamey, T.A.1
-
7
-
-
29744462375
-
Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: An update
-
16391327 10.1373/clinchem.2005.059170
-
Stephan C, Klaas M, Muller C, Schnorr D, Loening SA, Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem. 2006;52:59-64.
-
(2006)
Clin Chem
, vol.52
, pp. 59-64
-
-
Stephan, C.1
Klaas, M.2
Muller, C.3
Schnorr, D.4
Loening, S.A.5
Jung, K.6
-
8
-
-
33746633333
-
Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation
-
16762996 10.1373/clinchem.2006.069039
-
Kort S, Martens F, Vanpoucke H, et al. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006;52:1568-74.
-
(2006)
Clin Chem
, vol.52
, pp. 1568-1574
-
-
Kort, S.1
Martens, F.2
Vanpoucke, H.3
-
9
-
-
45949106975
-
Intermethod differences in results for total PSA, free PSA, and percentage of free PSA
-
18480013 10.1309/JYBPMFNUF6EYY9TB
-
Slev PR, La'ulu SL, Roberts WL. Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol. 2008;129:952-8.
-
(2008)
Am J Clin Pathol
, vol.129
, pp. 952-958
-
-
Slev, P.R.1
La'Ulu, S.L.2
Roberts, W.L.3
-
10
-
-
73349116583
-
Discordant total and free prostate-specific antigen (PSA) assays: Does calibration with WHO reference materials diminish the problem?
-
19778292 10.1515/CCLM.2009.285
-
Stephan C, Köpke T, Semjonow A, et al. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? Clin Chem Lab Med. 2009;47:1325-31.
-
(2009)
Clin Chem Lab Med
, vol.47
, pp. 1325-1331
-
-
Stephan, C.1
Köpke, T.2
Semjonow, A.3
-
11
-
-
84865335131
-
Standardization of assay methods reduces variability of total PSA measurements: An Irish study
-
22897326 10.1111/j.1464-410X.2011.10923.x
-
Forde JC, Marignol L, Blake O, et al. Standardization of assay methods reduces variability of total PSA measurements: an Irish study. BJU Int. 2012;110:644-50.
-
(2012)
BJU Int
, vol.110
, pp. 644-650
-
-
Forde, J.C.1
Marignol, L.2
Blake, O.3
-
12
-
-
30844455114
-
Prostate-specific antigen: Bias and molarity of commercial assays for PSA in use in England
-
16390608 10.1258/000456306775141731
-
Roddam AW, Rimmer J, Nickerson C, Ward AM. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem. 2006;43(Pt 1):35-48.
-
(2006)
Ann Clin Biochem
, vol.43
, Issue.PART 1
, pp. 35-48
-
-
Roddam, A.W.1
Rimmer, J.2
Nickerson, C.3
Ward, A.M.4
-
13
-
-
2642574977
-
Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: A simulation study based on the population of the United Kingdom
-
15031266 10.1373/clinchem.2004.031138
-
Roddam AW, Price CP, Allen NE, Ward AM. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem. 2004;50:1012-6.
-
(2004)
Clin Chem
, vol.50
, pp. 1012-1016
-
-
Roddam, A.W.1
Price, C.P.2
Allen, N.E.3
Ward, A.M.4
-
14
-
-
70349757756
-
-
American Urological Association Accessed 26 Jan 2013
-
American Urological Association. Prostate-Specific Antigen Best Practice Statement: 2009 update. http://www.auanet.org/content/guidelines-andquality- care/clinical-guidelines/mainreports/psa09.pdf (2009). Accessed 26 Jan 2013.
-
(2009)
Prostate-Specific Antigen Best Practice Statement: 2009 Update
-
-
-
16
-
-
0028073510
-
Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves
-
7525994
-
Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152:2031-6.
-
(1994)
J Urol
, vol.152
, pp. 2031-2036
-
-
Catalona, W.J.1
Richie, J.P.2
Dekernion, J.B.3
-
17
-
-
63249122661
-
Mortality results from a randomized prostate-cancer screening trial
-
2944770 19297565 10.1056/NEJMoa0810696
-
Andriole GL, Crawford ED, Grubb 3rd RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-9.
-
(2009)
N Engl J Med
, vol.360
, pp. 1310-1319
-
-
Andriole, G.L.1
Crawford, E.D.2
Grubb III, R.L.3
-
18
-
-
63249118690
-
Screening and prostate-cancer mortality in a randomized European study
-
19297566 10.1056/NEJMoa0810084
-
Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
-
(2009)
N Engl J Med
, vol.360
, pp. 1320-1328
-
-
Schröder, F.H.1
Hugosson, J.2
Roobol, M.J.3
-
19
-
-
57149088140
-
Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection
-
18927249 10.1373/clinchem.2007.102699
-
Jansen FH, Roobol M, Bangma CH, van Schaik RH. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem. 2008;54:1999-2006.
-
(2008)
Clin Chem
, vol.54
, pp. 1999-2006
-
-
Jansen, F.H.1
Roobol, M.2
Bangma, C.H.3
Van Schaik, R.H.4
-
20
-
-
33846002787
-
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes
-
17222629 10.1016/j.juro.2006.10.097
-
Cookson MS, Aus G, Burnett AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177:540-5.
-
(2007)
J Urol
, vol.177
, pp. 540-545
-
-
Cookson, M.S.1
Aus, G.2
Burnett, A.L.3
-
21
-
-
77649195776
-
WHO standarization of PSA tests: Clinical consequences
-
19498407 10.1038/nrurol.2009.94
-
Stephan C. WHO standarization of PSA tests: clinical consequences. Nat Rev Urol. 2009;6:303-5.
-
(2009)
Nat Rev Urol
, vol.6
, pp. 303-305
-
-
Stephan, C.1
|